- CurifyLabs has secured $14 million in Series A funding just 14 months after its last round. Sandwater and HealthCap co-led the round, with Tesi and Lifeline Ventures also participating.
- This Finnish healthtech company automates pharmacy compounding, a typically manual and error-prone process. Compounding creates custom-dosed medicines for children, cancer patients, and others who cannot use standard drugs.
- With this round, CurifyLabs’ total funding now exceeds $19 million.
In May 2025, CurifyLabs raised €6.7 million to support its pharmacy compounding automation. 14 months later, it secured another $14 million, with Sandwater and HealthCap co-leading the round, with Tesi and Lifeline Ventures also participating.
This quick pace of fundraising is unusual for a Series A healthtech company, especially one that already has grants and loans. Tech Funding News has not yet found out why the company needed capital so quickly.
Charlotta Topelius and her husband, Niklas Sandler, founded CurifyLabs in 2021. Sandler is a professor of pharmaceutical technology at Åbo Akademi University in Finland and has spent more than ten years researching automated compounding. Topelius, an experienced entrepreneur, founded the company based on his research. CurifyLabs is based in Helsinki and also has a US office in Jacksonville, Florida.
“This investment reflects the conviction our partners have in what we’re building. We have set a high bar for clinical rigour, product quality, and customer support, and this funding gives us the resources to raise that bar further,” says Topelius.
Right now, only 1% of drugs are personalised through compounding, even though demand is rising. CurifyLabs also says that 50% of medicines are not available in doses or forms approved for children. Closing this gap between demand and supply is at the core of CurifyLabs’ business model.
How the PharmaPrinter works and other companies in this field
Pharmacy compounding involves pharmacists manually preparing custom doses when standard pills or liquids are unsuitable, such as for children who cannot swallow tablets or patients allergic to certain ingredients. This process is slow and prone to human error.
CurifyLabs addresses this by combining GMP-manufactured excipient bases with software and a desktop device, the PharmaPrinter, which enables pharmacists to produce doses on-site with integrated quality checks. The system is now used in pharmacies across 21 US states and Europe.
The closest competitor is FabRx, a UK company that started at University College London in 2014. FabRx has developed its pharmaceutical 3D printing technology without outside funding and is only now planning its first funding round. FabRx has mainly focused on research and small-batch uses, while CurifyLabs has moved further into commercial pharmacy use. This is the main difference between the two companies.
Funding, investors, and open questions
The $14 million round was co-led by Sandwater and HealthCap, with Tesi (Finnish Industry Investment Ltd.), Lifeline Ventures, and unnamed US customers and employees also participating.
“CurifyLabs has built something rare, technology that combines clinical rigour with the speed and precision that busy pharmacy teams depend on,” says Morten E. Iversen, partner at Sandwater, which has previously backed digital health platform XO Life.
“We have backed more than 136 life sciences companies over nearly three decades, and what sets the best founders apart is their ability to combine scientific depth with real-world execution. The CurifyLabs team has done exactly that,” notes Daniel Karsberg, partner at HealthCap.
“CurifyLabs is the kind of company we want to support, innovative, globally ambitious, and built on deep scientific expertise. Their growth in the US is further proof that Finnish health technology can compete and win on the world stage,” adds Joni Karsikas, investment director at Tesi.
CurifyLabs said it will use the funding to grow its US operations, improve its supply chain, and speed up product development. The company has not said how much is left from the last round.
The global compounding pharmacy market was valued at about $15 billion, with an estimated 5.5% annual growth rate, according to earlier reports. It remains unclear whether this second rise in just over a year is due to careful scaling or to higher-than-expected US expansion costs.
